Human Genome Sciences
said Monday that H. Thomas Watkins has been appointed CEO, as well as a member of the company's board.
Watkins, 51, who recently served as president of TAP Pharmaceutical Products, which is jointly owned by
and Japan's Takeda Pharmaceutical, succeeds William A. Haseltine, the company's founder and former chairman and CEO, who retired Oct. 17.
Maryland-based Human Genome Sciences tries to treat and cure disease by creating gene-based protein and antibody drugs.
At one point during the heyday of the last bull market, it traded at more than $200 a share, or $100 on a split-adjusted basis. Shares ended at $10.47 Friday.
For the nine months ended Sept. 30, revenue decreased 15% to $3 million, while its net loss increased 29% to $176.2 million.